SABCS 2025 – Carrick sees a way forward in CDK7
The group will start a pivotal trial of samuraciclib following promising second-line results.
AstraZeneca becomes TIGIT's last man standing
Arcus steps back from TIGIT as its Fc-silent claim crumbles.
SABCS 2025 – Ember-3 brings no all-comers solace
Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
Baili moves its CD33 conjugate into advanced trials
The company is set to start a phase 2/3 trial this month.
Bristol challenges Adcetris on its own turf
Some time ago Opdivo beat Adcetris in an NCI trial, and now Bristol files.
SABCS 2025 – Gilead hasn’t given up on its Ascent
The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
SABCS 2025 – pumitamig replicates breast cancer findings
Global phase 2 data in TNBC look similar to earlier results in China.
SABCS 2025 – Roche mounts its early breast cancer challenge
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
ASH 2025 – Terns wins
The company might have blown Enliven out of the water.
ASH 2025 – J&J’s multiple myeloma juggling act
Tecvayli plus Darzalex could challenge Carvykti in the push for a functional cure.
